for mobile/tablet users, please navigate using the menu located below.
  No one can whistle a symphony. It takes a whole orchestra to play it.
~H.E. Luccock

 Our future success stories…

  (Spain) lead candidate, BN-201, for the treatment of various neurological disorders including MS and acute optical neuritis – co-funding full IND-enabling/preclinical tox program.
  (US) Phase 1 program for (EMB-001) in cocaine dependence by targeting the stress response system and specific brain functions that lead to craving and relapse.
  (UK) lead candidate, GLY2028, for treatment of mild to moderate psoriasis by targeting pathways involved in the immune/inflammatory response, coupled with the achievement of target organ selectivity – co-funding full IND-enabling/ preclinical tox program.
  (UK) continuous glucose monitoring system using a proprietary intravascular, optical fluorescence-based sensor – full clinical program including CE/ Registration Trials.
  (UK) lead candidate, ICT2588, attacks all forms of solid tumors while leaving healthy tissue unharmed – co-funding full IND-enabling/preclinical tox program.
  (US) post-marketing study (Phase IV) for its FDA-approved Prolieve® device for the treatment of Benign Prostatic Hyperplasia (BPH).


 Exits/ Previous companies with whom we have worked...

  (US) lead candidate, PT107, is a first-in-class therapeutic vaccine (PT 107) for the treatment of non-small cell lung cancer.
thrombo tech  

(Israel) peptide, THR-18, allows thrombolytic stroke medications to dissolve blood clots, diminish life-threatening side effects and improve efficacy. Acquired by D-Pharm in April 2012.

omni bio
  (US) alpha-1 antitrypsin ("AAT"), for the treatment of Type 1 diabetes.
  (UK) oxyntomodulin analogue, TKS1225, reduces food intake/body weight, for obesity. Acquired by Wyeth Pharmaceuticals on December 2008.
innate therapeutics   (New Zealand) immunomodulator microparticle technology to treat certain cancers, infections, and autoimmune diseases such as multiple sclerosis.
migco Pharmaceuticals
  (New Zealand) botantical natural product, MGX-008, for the prevention and treatment of migraines.
Investment Summary
Industry sector:   Therapeutics, biotech, start-up, med device/diagnostic, med-tech, small/specialty pharma
Size of investment:   30-70% cost of the development studies
Investment stage:   Preclinical, IND-enabling, tox, Phase I-III
Return on investment:   Equity, downstream royalties, milestone payments, etc.
Geography:   Primarily US, UK and rest of EU, Israel